Logo image of CR

CRANE CO (CR) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:CR - US2244081046 - Common Stock

178.89 USD
+2.73 (+1.55%)
Last: 11/21/2025, 8:20:49 PM
178.89 USD
0 (0%)
After Hours: 11/21/2025, 8:20:49 PM
Fundamental Rating

7

CR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 130 industry peers in the Machinery industry. CR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CR is quite expensive at the moment. It does show a decent growth rate. These ratings could make CR a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

CR had positive earnings in the past year.
CR had a positive operating cash flow in the past year.
Each year in the past 5 years CR has been profitable.
Of the past 5 years CR 4 years had a positive operating cash flow.
CR Yearly Net Income VS EBIT VS OCF VS FCFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

With an excellent Return On Assets value of 14.35%, CR belongs to the best of the industry, outperforming 93.85% of the companies in the same industry.
Looking at the Return On Equity, with a value of 18.61%, CR belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
CR has a Return On Invested Capital of 13.88%. This is amongst the best in the industry. CR outperforms 83.08% of its industry peers.
CR had an Average Return On Invested Capital over the past 3 years of 9.11%. This is in line with the industry average of 10.24%.
The 3 year average ROIC (9.11%) for CR is below the current ROIC(13.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 14.35%
ROE 18.61%
ROIC 13.88%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
CR Yearly ROA, ROE, ROICCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

The Profit Margin of CR (17.33%) is better than 93.85% of its industry peers.
In the last couple of years the Profit Margin of CR has grown nicely.
CR has a better Operating Margin (18.33%) than 85.38% of its industry peers.
CR's Operating Margin has improved in the last couple of years.
With a decent Gross Margin value of 43.41%, CR is doing good in the industry, outperforming 79.23% of the companies in the same industry.
In the last couple of years the Gross Margin of CR has grown nicely.
Industry RankSector Rank
OM 18.33%
PM (TTM) 17.33%
GM 43.41%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
CR Yearly Profit, Operating, Gross MarginsCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CR is still creating some value.
Compared to 1 year ago, CR has more shares outstanding
The number of shares outstanding for CR has been reduced compared to 5 years ago.
Compared to 1 year ago, CR has an improved debt to assets ratio.
CR Yearly Shares OutstandingCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CR Yearly Total Debt VS Total AssetsCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

CR has an Altman-Z score of 12.99. This indicates that CR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.99, CR belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
There is no outstanding debt for CR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.99
ROIC/WACC1.46
WACC9.53%
CR Yearly LT Debt VS Equity VS FCFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 3.27 indicates that CR has no problem at all paying its short term obligations.
With an excellent Current ratio value of 3.27, CR belongs to the best of the industry, outperforming 82.31% of the companies in the same industry.
CR has a Quick Ratio of 2.26. This indicates that CR is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.26, CR belongs to the best of the industry, outperforming 80.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.27
Quick Ratio 2.26
CR Yearly Current Assets VS Current LiabilitesCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

5

3. Growth

3.1 Past

CR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.21%, which is quite impressive.
Measured over the past years, CR shows a decrease in Earnings Per Share. The EPS has been decreasing by -3.00% on average per year.
The Revenue has decreased by -7.25% in the past year.
The Revenue has been decreasing by -8.28% on average over the past years.
EPS 1Y (TTM)20.21%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%18.84%
Revenue 1Y (TTM)-7.25%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-1.34%

3.2 Future

CR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.74% yearly.
The Revenue is expected to grow by 8.35% on average over the next years. This is quite good.
EPS Next Y17.73%
EPS Next 2Y14.71%
EPS Next 3Y14.85%
EPS Next 5Y13.74%
Revenue Next Year7.16%
Revenue Next 2Y9.95%
Revenue Next 3Y9.04%
Revenue Next 5Y8.35%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CR Yearly Revenue VS EstimatesCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
CR Yearly EPS VS EstimatesCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6 8

3

4. Valuation

4.1 Price/Earnings Ratio

CR is valuated quite expensively with a Price/Earnings ratio of 31.00.
63.08% of the companies in the same industry are cheaper than CR, based on the Price/Earnings ratio.
CR is valuated rather expensively when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 26.35, the valuation of CR can be described as expensive.
63.85% of the companies in the same industry are cheaper than CR, based on the Price/Forward Earnings ratio.
CR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 31
Fwd PE 26.35
CR Price Earnings VS Forward Price EarningsCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CR indicates a slightly more expensive valuation: CR is more expensive than 66.92% of the companies listed in the same industry.
CR's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CR is cheaper than 70.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.6
EV/EBITDA 22.4
CR Per share dataCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

CR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CR has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CR's earnings are expected to grow with 14.85% in the coming years.
PEG (NY)1.75
PEG (5Y)N/A
EPS Next 2Y14.71%
EPS Next 3Y14.85%

3

5. Dividend

5.1 Amount

CR has a yearly dividend return of 0.50%, which is pretty low.
Compared to an average industry Dividend Yield of 1.87, CR has a dividend in line with its industry peers.
With a Dividend Yield of 0.50, CR pays less dividend than the S&P500 average, which is at 2.45.
Industry RankSector Rank
Dividend Yield 0.5%

5.2 History

The dividend of CR decreases each year by -12.19%.
CR has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-12.19%
Div Incr Years0
Div Non Decr Years0
CR Yearly Dividends per shareCR Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

CR pays out 14.07% of its income as dividend. This is a sustainable payout ratio.
DP14.07%
EPS Next 2Y14.71%
EPS Next 3Y14.85%
CR Yearly Income VS Free CF VS DividendCR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M
CR Dividend Payout.CR Dividend Payout, showing the Payout Ratio.CR Dividend Payout.PayoutRetained Earnings

CRANE CO

NYSE:CR (11/21/2025, 8:20:49 PM)

After market: 178.89 0 (0%)

178.89

+2.73 (+1.55%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)01-27 2026-01-27/amc
Inst Owners77.38%
Inst Owner Change1.15%
Ins Owners0.27%
Ins Owner Change-0.18%
Market Cap10.30B
Revenue(TTM)2.11B
Net Income(TTM)365.90M
Analysts82.35
Price Target216.04 (20.77%)
Short Float %1.13%
Short Ratio1.9
Dividend
Industry RankSector Rank
Dividend Yield 0.5%
Yearly Dividend0.82
Dividend Growth(5Y)-12.19%
DP14.07%
Div Incr Years0
Div Non Decr Years0
Ex-Date11-28 2025-11-28 (0.23)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.41%
Min EPS beat(2)7.02%
Max EPS beat(2)7.79%
EPS beat(4)4
Avg EPS beat(4)4.58%
Min EPS beat(4)0.24%
Max EPS beat(4)7.79%
EPS beat(8)8
Avg EPS beat(8)4.11%
EPS beat(12)12
Avg EPS beat(12)9.6%
EPS beat(16)15
Avg EPS beat(16)7.95%
Revenue beat(2)0
Avg Revenue beat(2)-1.24%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-1.18%
Revenue beat(4)0
Avg Revenue beat(4)-1.19%
Min Revenue beat(4)-1.29%
Max Revenue beat(4)-1.07%
Revenue beat(8)1
Avg Revenue beat(8)-1.01%
Revenue beat(12)3
Avg Revenue beat(12)-4.21%
Revenue beat(16)5
Avg Revenue beat(16)-0.03%
PT rev (1m)0.48%
PT rev (3m)1.99%
EPS NQ rev (1m)-1.33%
EPS NQ rev (3m)-0.16%
EPS NY rev (1m)2.21%
EPS NY rev (3m)6.56%
Revenue NQ rev (1m)-1.48%
Revenue NQ rev (3m)-1.24%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)0.68%
Valuation
Industry RankSector Rank
PE 31
Fwd PE 26.35
P/S 4.88
P/FCF 18.6
P/OCF 16.92
P/B 5.24
P/tB 9.12
EV/EBITDA 22.4
EPS(TTM)5.77
EY3.23%
EPS(NY)6.79
Fwd EY3.8%
FCF(TTM)9.62
FCFY5.38%
OCF(TTM)10.57
OCFY5.91%
SpS36.69
BVpS34.17
TBVpS19.62
PEG (NY)1.75
PEG (5Y)N/A
Graham Number66.6
Profitability
Industry RankSector Rank
ROA 14.35%
ROE 18.61%
ROCE 17.94%
ROIC 13.88%
ROICexc 16.92%
ROICexgc 32.12%
OM 18.33%
PM (TTM) 17.33%
GM 43.41%
FCFM 26.22%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
ROICexc(3y)10.78%
ROICexc(5y)10.01%
ROICexgc(3y)18.74%
ROICexgc(5y)19.36%
ROCE(3y)12.01%
ROCE(5y)11.18%
ROICexgc growth 3Y10.29%
ROICexgc growth 5Y0.39%
ROICexc growth 3Y13.04%
ROICexc growth 5Y6.99%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 113.69%
Cap/Sales 2.6%
Interest Coverage 30
Cash Conversion 139.8%
Profit Quality 151.3%
Current Ratio 3.27
Quick Ratio 2.26
Altman-Z 12.99
F-Score8
WACC9.53%
ROIC/WACC1.46
Cap/Depr(3y)93.58%
Cap/Depr(5y)79.88%
Cap/Sales(3y)1.9%
Cap/Sales(5y)1.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.21%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%18.84%
EPS Next Y17.73%
EPS Next 2Y14.71%
EPS Next 3Y14.85%
EPS Next 5Y13.74%
Revenue 1Y (TTM)-7.25%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-1.34%
Revenue Next Year7.16%
Revenue Next 2Y9.95%
Revenue Next 3Y9.04%
Revenue Next 5Y8.35%
EBIT growth 1Y8.07%
EBIT growth 3Y17.08%
EBIT growth 5Y-5.09%
EBIT Next Year26.16%
EBIT Next 3Y18.66%
EBIT Next 5Y14.98%
FCF growth 1Y219.08%
FCF growth 3Y-20.47%
FCF growth 5Y-6.44%
OCF growth 1Y182.06%
OCF growth 3Y-18.53%
OCF growth 5Y-7.3%

CRANE CO / CR FAQ

What is the fundamental rating for CR stock?

ChartMill assigns a fundamental rating of 7 / 10 to CR.


What is the valuation status of CRANE CO (CR) stock?

ChartMill assigns a valuation rating of 3 / 10 to CRANE CO (CR). This can be considered as Overvalued.


What is the profitability of CR stock?

CRANE CO (CR) has a profitability rating of 9 / 10.


Can you provide the financial health for CR stock?

The financial health rating of CRANE CO (CR) is 9 / 10.


How sustainable is the dividend of CRANE CO (CR) stock?

The dividend rating of CRANE CO (CR) is 3 / 10 and the dividend payout ratio is 14.07%.